NSCLC CELL LINE WITH CROSS-RESISTANCE TO CETUXIMAB AND GEFITINIB AND METHOD OF SCREENING ANTICANCER DRUGS USING THE SAME

摘要

PURPOSE: An NSCLC cell line with cross-resistance to cetuximab and gefitinib and a method for screening an anticancer agent using the same are provided to ensure excellent therapeutic effect. CONSTITUTION: An NSCLC cell line has a cross-resistance to cetuximab and gefitinib. A method for screening a medicine for treating cancer comprises a step of treating candidate materials to the cell line and checking resistance overcome to cetuximab and gefitinib. The medicine is PI3K/Akt inhibitor. The cancer is lung cancer, breast cancer, or head and neck cancer. The PI3K/Akt inhibitor is a polyclonal antibody or monoclonal antibody to PI3K or Akt. The PI3K/Akt inhibitor is chemical formula 1.